Ganetespib: research and clinical development

Por Jhaveri, Komal, Modi, Shanu
Publicado no Onco Targets Ther (2015)

HER2 breast cancer therapies: a review

Por Murphy, Conleth G, Modi, Shanu
Publicado em 2009

Targeting the cyclin D–cyclin-dependent kinase (CDK)4/6–retinoblastoma pathway with selective CDK 4/6 inhibitors in hormone receptor-positive breast cancer: rationale, current stat...

Por Spring, Laura, Bardia, Aditya, Modi, Shanu
Publicado no Discov Med (2016)

Unlocking the potential of antibody–drug conjugates for cancer therapy

Por Drago, Joshua Z., Modi, Shanu, Chandarlapaty, Sarat
Publicado no Nat Rev Clin Oncol (2021)

Advances in the clinical development of heat shock protein 90 (Hsp90) inhibitors in cancers

Por Jhaveri, Komal, Taldone, Tony, Modi, Shanu, Chiosis, Gabriela
Publicado em 2011

Advances in the discovery and development of heat-shock protein 90 inhibitors for cancer treatment

Por Patel, Hardik J, Modi, Shanu, Chiosis, Gabriela, Taldone, Tony
Publicado em 2011

Chaperome heterogeneity and its implications for cancer study and treatment

Por Wang, Tai, Rodina, Anna, Dunphy, Mark P., Corben, Adriana, Modi, Shanu, Guzman, Monica L., Gewirth, Daniel T., Chiosis, Gabriela
Publicado no J Biol Chem (2019)

Ex Vivo Treatment Response of Primary Tumors and/or Associated Metastases for Preclinical and Clinical Development of Therapeutics

Por Corben, Adriana D., Uddin, Mohammad M., Crawford, Brooke, Farooq, Mohammad, Modi, Shanu, Gerecitano, John, Chiosis, Gabriela, Alpaugh, Mary L.
Publicado no J Vis Exp (2014)

Endocrine Therapy–Induced Alopecia in Patients With Breast Cancer

Por Freites-Martinez, Azael, Shapiro, Jerry, Chan, Donald, Fornier, Monica, Modi, Shanu, Gajria, Devika, Dusza, Stephen, Goldfarb, Shari, Lacouture, Mario E.
Publicado no JAMA Dermatol (2018)

Phase 1b/2a study of trastuzumab emtansine (T-DM1), paclitaxel, and pertuzumab in HER2-positive metastatic breast cancer

Por Krop, Ian E., Modi, Shanu, LoRusso, Patricia M., Pegram, Mark, Guardino, Ellie, Althaus, Betsy, Lu, Dan, Strasak, Alexander, Elias, Anthony
Publicado no Breast Cancer Res (2016)

The Effect of Molecular Subtype and Residual Disease on Locoregional Recurrence in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy and Postmastectomy Radiation

Por Yang, T. Jonathan, Morrow, Monica, Modi, Shanu, Zhang, Zhigang, Krause, Kate, Siu, Chun, McCormick, Beryl, Powell, Simon N., Ho, Alice Y.
Publicado no Ann Surg Oncol (2015)

A multicenter trial evaluating retaspimycin HCL (IPI-504) plus trastuzumab in patients with advanced or metastatic HER2-positive breast cancer

Por Modi, Shanu, Saura, Cristina, Henderson, Charles, Lin, Nancy U., Mahtani, Reshma, Goddard, Jill, Rodenas, Eduardo, Hudis, Clifford, O’Shaughnessy, Joyce, Baselga, Jose
Publicado em 2013

Phase II Study of Weekly Paclitaxel with Trastuzumab and Pertuzumab in Patients with Human Epidermal Growth Receptor 2 Overexpressing Metastatic Breast Cancer: 5‐Year Follow‐up

Por Wang, Rui, Smyth, Lillian M., Iyengar, Neil, Chandarlapaty, Sarat, Modi, Shanu, Jochelson, Maxine, Patil, Sujata, Norton, Larry, Hudis, Clifford A., Dang, Chau T.
Publicado no Oncologist (2019)

Frequent mutational activation of the PI3K-AKT pathway in trastuzumab-resistant breast cancer

Por Chandarlapaty, Sarat, Sakr, Rita A., Giri, Dilip, Patil, Sujata, Heguy, Adriana, Morrow, Monica, Modi, Shanu, Norton, Larry, Rosen, Neal, Hudis, Clifford, King, Tari A.
Publicado em 2012

Increased levels of urinary PGE-M, a biomarker of inflammation, occur in association with obesity, aging and lung metastases in patients with breast cancer

Por Morris, Patrick G., Zhou, Xi Kathy, Milne, Ginger L., Goldstein, Daniel, Hawks, Laura C., Dang, Chau T., Modi, Shanu, Fornier, Monica N., Hudis, Clifford A., Dannenberg, Andrew J.
Publicado em 2013

A Phase I study of alpelisib in combination with trastuzumab and LJM716 in patients with PIK3CA-mutated HER2-positive metastatic breast cancer

Por Jhaveri, Komal, Drago, Joshua Z., Shah, Payal Deepak, Wang, Rui, Pareja, Fresia, Ratzon, Fanni, Iasonos, Alexia, Patil, Sujata, Rosen, Neal, Fornier, Monica N., Sklarin, Nancy T., Chandarlapaty, Sarat, Modi, Shanu
Publicado no Clin Cancer Res (2021)

Assessment of Quality of Life and Treatment Outcomes of Patients With Persistent Postchemotherapy Alopecia

Por Freites-Martinez, Azael, Chan, Donald, Sibaud, Vincent, Shapiro, Jerry, Fabbrocini, Gabriella, Tosti, Antonella, Cho, Juhee, Goldfarb, Shari, Modi, Shanu, Gajria, Devika, Norton, Larry, Paus, Ralf, Cigler, Tessa, Lacouture, Mario E.
Publicado no JAMA Dermatol (2019)

Heat shock protein 90 inhibitors in the treatment of cancer: current status and future directions

Por Jhaveri, Komal, Ochiana, Stefan O, Dunphy, Mark PS, Gerecitano, John F, Corben, Adriana D, Peter, Radu I, Janjigian, Yelena Y, Gomes-DaGama, Erica M, Koren, John, Modi, Shanu, Chiosis, Gabriela
Publicado em 2014

Biomarkers that Predict Sensitivity to Heat Shock Protein 90 Inhibitors (HSP90i)

Por Jhaveri, Komal, Chandarlapaty, Sarat, Iyengar, Neil, Morris, Patrick G., Corben, Adriana D, Patil, Sujata, Akram, Muzaffar, Towers, Russell, Sakr, Rita A, King, Tari A, Norton, Larry, Rosen, Neal, Hudis, Clifford, Modi, Shanu
Publicado no Clin Breast Cancer (2015)

Pilot study of (68)Ga-DOTA-F(ab′)(2)-trastuzumab in patients with breast cancer

Por Beylergil, Volkan, Morris, Patrick G., Smith-Jones, Peter M., Modi, Shanu, Solit, David, Hudis, Clifford A., Lu, Yang, O’Donoghue, Joseph, Lyashchenko, Serge K., Carrasquillo, Jorge A., Larson, Steven M., Akhurst, Timothy J.
Publicado em 2013